Healthcare
Vertex Pharmaceuticals Incorporated(VRTX)
Live Price
Offline$451.63
-1.60% today
1Y Change
+1.82%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $109.34B
- Revenue Growth
- +9.6%
- EPS Growth
- +843.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vertex Pharmaceuticals Incorporated (VRTX) is a Healthcare stock with a market cap of $109.34B and listed on NASDAQ. The stock last traded around $451.63 and up 1.8% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +9.6%, EPS growth of +843.3%, a dividend yield of 0.0%. What stands out right now is revenue +9.6%, EPS +843.3%, free cash flow +504.1% with operating margin 35.5% and ROIC 16.2%. Valuation already assumes a fairly strong business story at P/E 27.6 and price/sales 9.1. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines VRTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+9.6% vs +7.6% peer median
Operating Margin
Above sector median
+35.5% vs +19.4% peer median
P/E
Below sector median
27.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +9.6% and EPS at +843.3%, with operating margin around 35.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -1.3% | +1.2% | -1.1% |
2026 Feb 12, 2026 | -1.6% | +5.7% | +2.6% | +0.9% |
2025 Nov 3, 2025 | +5.0% | -1.0% | -1.1% | +1.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRTX Max Drawdown
-23.56%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRTX and SPY.
Company Overview
Vertex Pharmaceuticals Incorporated
NASDAQ Global Select
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
- Leadership
- Reshma Kewalramani
- IPO Date
- Jul 24, 1991
- Employees
- 6.1k
- Street Address
- 50 Northern Avenue
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 341 6100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 27.6
- EV/EBITDA
- 22.4
- Price/Sales
- 9.1
- Price/Book
- 5.8
Growth
- Revenue
- +9.6%
- EPS
- +843.3%
- Free Cash Flow
- +504.1%
Profitability
- Gross Margin
- 86.3%
- Operating Margin
- 35.5%
- Net Margin
- 32.8%
- ROE
- 22.7%
- ROIC
- 16.2%
Balance Sheet
- Debt/Equity
- 0.21
- Current Ratio
- 2.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.